These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21848469)

  • 1. Alemtuzumab in kidney-transplant recipients.
    Luan FL
    N Engl J Med; 2011 Aug; 365(7):671; author reply 671-2. PubMed ID: 21848469
    [No Abstract]   [Full Text] [Related]  

  • 2. Alemtuzumab in kidney-transplant recipients.
    Markmann JF; Fishman JA
    N Engl J Med; 2011 May; 364(20):1968-9. PubMed ID: 21591949
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab induction in renal transplantation.
    Hanaway MJ; Woodle ES; Mulgaonkar S; Peddi VR; Kaufman DB; First MR; Croy R; Holman J;
    N Engl J Med; 2011 May; 364(20):1909-19. PubMed ID: 21591943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death.
    Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA
    Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
    Plata-Munoz JJ; Vaidya A; Fuggle SV; Friend PJ
    Transpl Int; 2009 Oct; 22(10):1024-7. PubMed ID: 19624499
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab induction therapy in kidney transplantation.
    Dhaun N; Kluth DC
    Lancet; 2015 Feb; 385(9970):770. PubMed ID: 25752171
    [No Abstract]   [Full Text] [Related]  

  • 10. Alemtuzumab induction therapy in kidney transplantation.
    Berghofen A; Singer T; Krüger B; Krämer BK; Benck U
    Lancet; 2015 Feb; 385(9970):770-1. PubMed ID: 25752170
    [No Abstract]   [Full Text] [Related]  

  • 11. Alemtuzumab induction therapy in kidney transplantation.
    Kuypers DR
    Lancet; 2014 Nov; 384(9955):1649-51. PubMed ID: 25078307
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to Gaber.
    Sollinger H; Neidlinger NA
    Transplant Proc; 2010 Jun; 42(5):1401. PubMed ID: 20620443
    [No Abstract]   [Full Text] [Related]  

  • 13. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
    Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
    Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy.
    Heidt S; Shankar S; Muthusamy AS; San Segundo D; Wood KJ
    Transplantation; 2011 Apr; 91(8):e59-61. PubMed ID: 21475065
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab induction therapy in kidney transplantation - Authors' reply.
    Haynes R; Baigent C; Landray MJ; Harden P; Friend P
    Lancet; 2015 Feb; 385(9970):771. PubMed ID: 25752173
    [No Abstract]   [Full Text] [Related]  

  • 16. Finding the right job for the tool: alemtuzumab and its role in renal transplantation.
    Newell KA; Cendales LC; Kirk AD
    Am J Transplant; 2008 Jul; 8(7):1363-4. PubMed ID: 18557735
    [No Abstract]   [Full Text] [Related]  

  • 17. [Monoclonal antibodies in renal transplantation].
    Bonvoisin C; Weekers L; Grosch S; Krzesinski JM
    Rev Med Liege; 2009; 64(5-6):287-92. PubMed ID: 19642461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A; Sundberg A; Moore P; Hartmann E; Rogers J; Doares W; Jarrett A; Adams P; Stratta R
    Clin Transplant; 2008; 22(1):41-9. PubMed ID: 18217904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabbit antithymocyte globulin or basiliximab for induction therapy?
    Josephson MA
    N Engl J Med; 2006 Nov; 355(19):2033-5. PubMed ID: 17093255
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction therapy in pediatric kidney transplant recipients discharged with a triple drug immunosuppressive regimen.
    Sampaio MS; Poommipanit N; Kuo HT; Reddy PN; Cho YW; Shah T; Bunnapradist S
    Pediatr Transplant; 2010 Sep; 14(6):770-8. PubMed ID: 20477974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.